Qiagen inks companion Dx deal with Bayer

Qiagen ($QGEN) has signed on with Bayer to develop companion diagnostics for Bayer's solid tumor treatments, using the company's QIAsymphony Dx platform. The duo didn't disclose financial details, but Qiagen will work on molecular tests to guide the use of Bayer's existing cancer drugs, and the two will collaborate on new patient-profiling technologies. The partnership adds to Qiagen's companion Dx portfolio, and the company said it's in the midst of more than 15 projects with pharma and biotech companies. Release

Suggested Articles

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.

CMR Surgical will have a new CEO at the top of the year, as it kicks off the global launch of its modular Versius system while awaiting FDA approval.

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.